Results 161 to 170 of about 2,000 (177)

Emergence of in vitro resistance to lenacapavir is similar across HIV-1 subtypes.

AIDS (London)
OBJECTIVE To assess the potential in vitro emergence of resistance mutations to the capsid inhibitor lenacapavir (LEN) in clinical samples from subtype B versus non-B HIV-1 subtype.
Vidula Naik, Anurag Nekkalapudi, Archana V Boopathy, Brie Falkard, Christian Callebaut, N. Margot   +5 more
semanticscholar   +1 more source

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study.

AIDS (London)
OBJECTIVE To assess final efficacy (through Week [W] 132), safety, and emergent resistance with lenacapavir-based combination regimens in the CALIBRATE study. DESIGN CALIBRATE was a Phase 2, randomized, open-label study (NCT04143594).
D. Hagins, M. Berhe, G. Crofoot, M. Ramgopal, James Sims, C. Mcdonald, P. Ruane, William E. Sanchez, Anita Scribner, P. Benson, Shan-Yu Liu, Laurie A Vanderveen, H. Dvory‐Sobol, Martin S. Rhee, Samir K. Gupta   +14 more
semanticscholar   +1 more source

Lenacapavir to prevent HIV infection: current prices versus estimated costs of production.

Journal of Antimicrobial Chemotherapy
BACKGROUND Despite improvements in treatment and oral pre-exposure prophylaxis (PrEP) access, 1.3 million people acquired HIV in 2022. Six-monthly lenacapavir PrEP could benefit tens of millions of people at high risk of infection.
Andrew Hill, Jacob Levi, Cassandra Fairhead, Victoria Pilkington, Jun-Zheng Wang, Madison Johnson, Jevon Layne, David Roberts, Joseph Fortunak   +8 more
semanticscholar   +1 more source

Lenacapavir: a first-in-class capsid inhibitor for HIV treatment and prevention

Current Opinion in Infectious Diseases
Purpose of review This review summarizes available data for lenacapavir (LEN), a first-in-class agent that targets several functions of the HIV capsid in the viral cycle, including nuclear entry, viral assembly, and capsid formation.
M. McKellar
semanticscholar   +1 more source

FDA-Approved HIV-1 Capsid Inhibition With Lenacapavir: A Paradigm Shift in Pre-exposure Prophylaxis

Cureus
Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge, with over 40 million people currently living with the infection.
Kashaf Sanaullah, Abdul Haseeb Hasan, Muhammad Ali Abid   +2 more
semanticscholar   +1 more source

Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options

Expert Review of Anti-Infective Therapy, 2023
Onyema Ogbuagu, Jessica Tuan
exaly  

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

Medicina (Lithuania), 2023
Nouf Alotaibi, Mehnaz Kamal
exaly  

Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.

Journal of Infectious Diseases
J. Eron, Paul P. Cook, M. Mehrotra, Hai-Lin Huang, M. Caskey, G. Crofoot, Linda Gorgos, Laurie A Vanderveen, Yanan Zheng, Sean E. Collins, O. Osiyemi, C. Brinson, Edwin Dejesus   +12 more
semanticscholar   +1 more source

Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV

Expert Opinion on Pharmacotherapy, 2023
exaly  

Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV

American Journal of Health-System Pharmacy, 2023
exaly